metronidazole will enhance the amount or outcome of quetiapine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
Observe Intently (1)tipranavir will reduce the extent or influence of quetiapine by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
Postmarketing situations clearly show QT prolongation with overdose in individuals with concomitant disease or with prescription drugs identified to bring about electrolyte imbalance or lengthen QT.
oxaliplatin will increase the level or impact of quetiapine by Other (see comment). Use Caution/Monitor. Keep track of for ECG adjustments if therapy is initiated in sufferers with medications acknowledged to extend QT interval.
Postmarketing instances demonstrate QT prolongation with overdose in patients with concomitant sickness or with medicine known to result in electrolyte imbalance or extend QT.
Postmarketing conditions exhibit QT prolongation with overdose in individuals with concomitant illness or with medicine identified to cause electrolyte imbalance or extend QT.
Stay away from or substitute another drug for these drugs when possible. Appraise for lack of therapeutic result if medication must be coadministered. Alter dose according to prescribing data if needed.
haloperidol and quetiapine both equally improve antidopaminergic outcomes, such as extrapyramidal indications and neuroleptic malignant syndrome. Use Caution/Observe.
Postmarketing instances present QT prolongation with overdose in sufferers with concomitant ailment or with prescription drugs known to trigger electrolyte imbalance or prolong QT.
ozanimod and quetiapine equally boost QTc interval. Modify Therapy/Monitor Carefully. The prospective additive consequences on heart rate, cure with ozanimod must generally not be initiated in clients who are concurrently addressed with QT prolonging medicines with known arrhythmogenic Houses.
Postmarketing instances present QT prolongation with overdose in clients with concomitant health issues or with drugs recognized to result in electrolyte imbalance or extend QT.
inotuzumab and quetiapine both equally raise QTc interval. Stay clear of or Use Alternate Drug. If struggling to stay clear of concomitant use, attain ECGs and electrolytes right before and after initiation of any drug known to lengthen QTc, and periodically observe as clinically indicated all through cure.
Postmarketing conditions demonstrate QT prolongation with overdose in individuals with concomitant health issues or with medicine identified to cause electrolyte imbalance or extend QT.
rufinamide will click here decrease the extent or result of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.